FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 511 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI EMA Recommends Granting a Conditional Marketing Authorisation for Nogapendekin alfa Inbakicept MOST POPULAR Efficacy of Sintilimab in the Adjuvant Treatment for Patients with Resected,... January 26, 2024 New targeted treatment for early breast cancer could reduce risk of... July 21, 2022 EMA Recommends Granting a Marketing Authorisation for Celdoxome Pegylated Liposomal September 1, 2022 German Shepherds Detect Fast-Growing Form Of Breast Cancer And Save Their... February 18, 2020 Load more HOT NEWS Inhibition of GDF-15 with Ponsegromab Results in Increased Weight Gain and... The rise of the ‘long-waiter’ – why cancer waiting times are... New Approach May Help People with Cancer Better Manage Depression, Pain,... Will This Cancer Metastasize? Check Its “Stickiness”
